Moderna (MRNA) Doses First Participants in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. NVDA
6. MSFT
7. SKYD
8. BBIO
9. SPY
10. RCKT

Go back to Moderna (MRNA) Doses First Participants in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)

Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)

June 7, 2022 7:02 AM EDT

mRNA-1010 is Moderna's first seasonal influenza vaccine candidate to enter a Phase 3 trial
mRNA-1010 is one of several influenza vaccine candidates being developed in Moderna's respiratory portfolio
Moderna now has four programs in Phase 3 studies: Omicron-containing bivalent COVID booster, influenza, RSV, CMV

CAMBRIDGE, MA / ACCESSWIRE / June 7, 2022 / Moderna, Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first participants have been dosed in a Phase 3 study of the Company's seasonal influenza vaccine candidate (mRNA-1010).... More